Endocrinology
Type 2 Diabetes
Type 2 diabetes management should pair individualized glycemic targets with early selection of therapies that reduce cardiovascular, heart failure, kidney, weight, and hypoglycemia risk—not simply A1C. Reassess medication effectiveness, safety, affordability, and treatment burden every 3–6 months.
Clinical approach
Choose therapy by organ risk and treatment burden
A1C reduction remains important, but drug choice should address the complication most likely to affect the patient next.
Use shared decision-making to select therapy based on glucose-lowering efficacy, weight effects, ASCVD, heart failure, CKD, hypoglycemia risk, adverse effects, regimen complexity, access, and cost. Review the medication plan and medication-taking behavior every 3–6 months; do not delay intensification or deintensification when individualized goals are not met. ccjmccjm9. Pharmacologic Approaches to Glycemic Treatment
For adults without established ASCVD, heart failure, or CKD, metformin remains a common foundational therapy because it is effective, inexpensive, weight neutral, and rarely causes hypoglycemia. Gastrointestinal effects can often be mitigated by slow titration or extended-release formulation. Metformin may be used with eGFR ≥30 mL/min/1.73 m²; do not initiate it below eGFR 45 mL/min/1.73 m², reduce dose below 45 mL/min/1.73 m², and stop below 30 mL/min/1.73 m². Periodically consider vitamin B12 assessment, particularly with neuropathy or long-term exposure. ccjmccjm9. Pharmacologic Approaches to Glycemic Treatment
Avoid concurrent DPP-4 inhibitor and GLP-1 receptor agonist or dual GIP/GLP-1 receptor agonist therapy because it adds no meaningful glucose lowering. ccjmccjm9. Pharmacologic Approaches to Glycemic Treatment
When initiating a drug that lowers glucose without intrinsically causing hypoglycemia, reassess insulin, sulfonylurea, and meglitinide doses to reduce hypoglycemia and treatment burden. ccjmccjm9. Pharmacologic Approaches to Glycemic Treatment
Assess financial barriers routinely; lower-cost options include metformin, sulfonylureas, thiazolidinediones, and human insulin, but these trade lower acquisition cost for greater risks of hypoglycemia, weight gain, or other adverse effects. ccjmccjm9. Pharmacologic Approaches to Glycemic Treatment
| Clinical phenotype | Preferred glucose-lowering strategy | Key implementation point |
|---|---|---|
| Established ASCVD or high ASCVD risk | GLP-1 receptor agonist and/or SGLT2 inhibitor with demonstrated cardiovascular benefit. ccjmccjm9. Pharmacologic Approaches to Glycemic Treatment | Use irrespective of baseline A1C, A1C goal, or metformin use. ccjmccjm9. Pharmacologic Approaches to Glycemic Treatment |
| Heart failure, reduced or preserved ejection fraction | SGLT2 inhibitor. ccjmccjm9. Pharmacologic Approaches to Glycemic Treatment | Recommended for glycemic management and prevention of heart failure hospitalization irrespective of A1C. ccjmccjm9. Pharmacologic Approaches to Glycemic Treatment |
| CKD with eGFR 20–60 mL/min/1.73 m² and/or albuminuria | SGLT2 inhibitor or GLP-1 receptor agonist with demonstrated benefit. ccjmccjm9. Pharmacologic Approaches to Glycemic Treatment | SGLT2 inhibitor glycemic effect declines below eGFR 45 mL/min/1.73 m², but cardiorenal benefit remains a central reason for use. ccjmccjm9. Pharmacologic Approaches to Glycemic Treatment |
| Advanced CKD, eGFR <30 mL/min/1.73 m² | GLP-1 receptor agonist preferred for glycemic management. ccjmccjm9. Pharmacologic Approaches to Glycemic Treatment | Lower hypoglycemia risk and cardiovascular event reduction support preference. ccjmccjm9. Pharmacologic Approaches to Glycemic Treatment |
| Obesity with need for glucose lowering | Prioritize weight-lowering agents when appropriate; tirzepatide and semaglutide have highest glucose- and weight-lowering efficacy among listed agents. ccjmccjm9. Pharmacologic Approaches to Glycemic Treatment | Avoid unnecessary insulin, sulfonylurea, or thiazolidinedione exposure when alternatives can meet goals. ccjmccjm9. Pharmacologic Approaches to Glycemic Treatment |
Monitoring
Set glycemic goals that can be attained safely
Targets should change with life expectancy, comorbidity, hypoglycemia risk, and patient priorities.
For many nonpregnant adults, target A1C <7%, preprandial capillary glucose 80–130 mg/dL, and peak postprandial glucose <180 mg/dL measured 1–2 hours after beginning a meal. Lower A1C can be reasonable when achieved without frequent or severe hypoglycemia or excessive burden; less stringent goals may be appropriate when harms exceed expected benefit. ccjmccjm6. Glycemic Goals and Hypoglycemia: Standards of Care in ...
Measure A1C at least twice yearly when stable and at goal; assess about every 3 months with recent treatment change, lack of goal attainment, frequent severe dysglycemia, or changing health status. Use CGM metrics, BGM, fructosamine, or glycated albumin when A1C is unreliable because of altered red-cell turnover, hemoglobin disorders, transfusion, end-stage kidney disease, or pregnancy. ccjmccjm6. Glycemic Goals and Hypoglycemia: Standards of Care in ...
For CGM users, obtain at least 14 days of data with ≥70% active wear when using patterns for clinical decisions. Typical goals for many adults are time in range 70–180 mg/dL >70%, time below 70 mg/dL <4%, time below 54 mg/dL <1%, time above 180 mg/dL <25%, and time above 250 mg/dL <5%. ccjmccjm6. Glycemic Goals and Hypoglycemia: Standards of Care in ...
Assess A1C together with CGM or BGM when glycemic variability, hypoglycemia, or A1C–glucose discordance is likely. ccjmccjm6. Glycemic Goals and Hypoglycemia: Standards of Care in ...
Deintensify insulin, sulfonylureas, or meglitinides, or substitute lower-hypoglycemia-risk therapy, when hypoglycemia risk is high or treatment burdens exceed benefit. ccjmccjm6. Glycemic Goals and Hypoglycemia: Standards of Care in ...
Any level 2 hypoglycemia (<54 mg/dL) or level 3 event requiring assistance should trigger prompt treatment-plan reevaluation. ccjmccjm6. Glycemic Goals and Hypoglycemia: Standards of Care in ...
| Measure | Usual target | Action when off target |
|---|---|---|
| A1C | <7% for many adults. ccjmccjm6. Glycemic Goals and Hypoglycemia: Standards of Care in ... | Individualize upward or downward according to safety, life expectancy, comorbidity, and treatment burden. ccjmccjm6. Glycemic Goals and Hypoglycemia: Standards of Care in ... |
| Preprandial capillary glucose | 80–130 mg/dL. ccjmccjm6. Glycemic Goals and Hypoglycemia: Standards of Care in ... | Review basal therapy, meal timing, adherence, and hypoglycemia exposure before titration. ccjmccjm6. Glycemic Goals and Hypoglycemia: Standards of Care in ... |
| Peak postprandial capillary glucose | <180 mg/dL 1–2 hours after meal start. ccjmccjm6. Glycemic Goals and Hypoglycemia: Standards of Care in ... | Address meal-related hyperglycemia when A1C remains above goal despite preprandial targets. ccjmccjm6. Glycemic Goals and Hypoglycemia: Standards of Care in ... |
| CGM time in range, 70–180 mg/dL | 70% for most adults; >50% for older adults. ccjmccjm6. Glycemic Goals and Hypoglycemia: Standards of Care in ... | Prioritize reduction of time below range before pursuing tighter hyperglycemia targets. ccjmccjm6. Glycemic Goals and Hypoglycemia: Standards of Care in ... |
Pharmacotherapy
Use insulin selectively and safely
Insulin is essential in severe hyperglycemia or insulin deficiency, but not automatically the next injectable option.
Consider insulin regardless of current therapy when symptoms of hyperglycemia or catabolic features are present, or when A1C exceeds 10% or blood glucose is ≥300 mg/dL. In adults without evidence of insulin deficiency, a GLP-1 receptor agonist, including a dual GIP/GLP-1 receptor agonist, is preferred to insulin because of favorable hypoglycemia and weight effects. ccjmccjm9. Pharmacologic Approaches to Glycemic Treatment
When basal insulin is required, a typical starting dose is 0.1–0.2 units/kg/day with individualized titration over days to weeks. If fasting glucose is controlled but A1C remains elevated, evaluate for postprandial hyperglycemia or overbasalization rather than simply escalating basal insulin. Signals include bedtime-to-morning or preprandial-to-postprandial differentials of at least 50 mg/dL, hypoglycemia, or high glycemic variability. ccjmccjm9. Pharmacologic Approaches to Glycemic Treatment
If basal insulin alone is insufficient, add a GLP-1 receptor agonist or dual GIP/GLP-1 receptor agonist before prandial insulin when feasible. If prandial insulin is needed, begin with 4 units or 10% of the basal dose at the largest meal or meal with the greatest postprandial excursion, then intensify according to glucose data. ccjmccjm9. Pharmacologic Approaches to Glycemic Treatment
Long-acting insulin analogs reduce nocturnal and level 2 hypoglycemia compared with NPH insulin; degludec or glargine U-300 can reduce nocturnal hypoglycemia relative to glargine U-100. ccjmccjm9. Pharmacologic Approaches to Glycemic Treatment
Continue metformin, SGLT2 inhibitors, and GLP-1 receptor agonists during insulin intensification unless contraindicated or not tolerated, because they may preserve metabolic, cardiorenal, or weight benefits. ccjmccjm9. Pharmacologic Approaches to Glycemic Treatment
Limit or stop sulfonylureas, meglitinides, and DPP-4 inhibitors during complex insulin intensification when they add little benefit or increase hypoglycemia and weight burden. ccjmccjm9. Pharmacologic Approaches to Glycemic Treatment
| Situation | Preferred next step | Safety issue |
|---|---|---|
| Symptomatic hyperglycemia, catabolism, A1C >10%, or glucose ≥300 mg/dL | Initiate insulin; simplify later if glucose toxicity resolves and noninsulin therapy becomes adequate. ccjmccjm9. Pharmacologic Approaches to Glycemic Treatment | Provide education on glucose monitoring, sick-day management, and hypoglycemia prevention. ccjmccjm9. Pharmacologic Approaches to Glycemic Treatment |
| Insulin-naive patient requiring basal insulin | Start basal insulin 0.1–0.2 units/kg/day and titrate. ccjmccjm9. Pharmacologic Approaches to Glycemic Treatment | Avoid excessive basal escalation when fasting glucose is controlled but A1C remains elevated. ccjmccjm9. Pharmacologic Approaches to Glycemic Treatment |
| Basal insulin optimized but postprandial hyperglycemia persists | Add GLP-1 receptor agonist or dual GIP/GLP-1 receptor agonist if not already used; otherwise add prandial insulin. ccjmccjm9. Pharmacologic Approaches to Glycemic Treatment | Reassess basal dose when substantial prandial insulin is added to avoid hypoglycemia. ccjmccjm9. Pharmacologic Approaches to Glycemic Treatment |
| Need for first prandial dose | Start 4 units or 10% of basal insulin at largest meal. ccjmccjm9. Pharmacologic Approaches to Glycemic Treatment | Use BGM or CGM patterns to titrate; coordinate insulin with food intake. ccjmccjm9. Pharmacologic Approaches to Glycemic Treatment |
Safety
Prevent hypoglycemia and ketoacidosis
Medication safety planning is most important when insulin, secretagogues, or SGLT inhibition are used.
Review hypoglycemia at every encounter in people using insulin, sulfonylureas, or meglitinides. High-risk features include recent level 2 or 3 hypoglycemia, impaired awareness, intensive insulin therapy, end-stage kidney disease, cognitive impairment, food insecurity, low income, housing insecurity, and fasting. CGM is recommended for individuals at high hypoglycemia risk. ccjmccjm6. Glycemic Goals and Hypoglycemia: Standards of Care in ...
Treat conscious hypoglycemia at glucose <70 mg/dL with fast-acting carbohydrate, typically 15 g, and recheck after 15 minutes. Avoid high-fat or high-protein foods for initial rescue. Prescribe glucagon for all people taking insulin or at high hypoglycemia risk; ready-to-use intranasal or injectable products are preferred because they do not require reconstitution. ccjmccjm6. Glycemic Goals and Hypoglycemia: Standards of Care in ...
SGLT2 inhibitors can precipitate ketoacidosis with lower-than-expected glucose. In type 2 diabetes, reported DKA incidence is 0.6–4.9 events per 1,000 patient-years; risk factors include carbohydrate restriction, prolonged fasting, dehydration, excess alcohol, acute illness, and insulin deficiency. Educate patients to recognize nausea, vomiting, abdominal pain, malaise, and dyspnea; assess ketones despite modest glucose elevation when symptoms occur. ccjm+1ccjm9. Pharmacologic Approaches to Glycemic Treatmentccjm6. Glycemic Goals and Hypoglycemia: Standards of Care in ...
SGLT2 inhibitors are not approved for type 1 diabetes because DKA risk is substantially increased. ccjmccjm9. Pharmacologic Approaches to Glycemic Treatment
For planned surgery, discontinue SGLT2 inhibitors 3–4 days beforehand; FDA labeling cited in hospital guidance specifies 4 days for ertugliflozin. ccjmccjm16. Diabetes Care in the Hospital: Standards of Care in Diabetes—2024
During illness or fasting, insulin-treated patients should not omit basal insulin; intensify glucose and ketone monitoring when clinically indicated. ccjmccjm6. Glycemic Goals and Hypoglycemia: Standards of Care in ...
| Trigger | Immediate clinical response | Why it matters |
|---|---|---|
| Level 2 hypoglycemia, glucose <54 mg/dL | Reevaluate and deintensify or modify hypoglycemia-causing therapy. ccjmccjm6. Glycemic Goals and Hypoglycemia: Standards of Care in ... | Signals high risk for recurrent severe hypoglycemia. ccjmccjm6. Glycemic Goals and Hypoglycemia: Standards of Care in ... |
| Illness, prolonged fasting, vomiting, or carbohydrate restriction while using SGLT2 inhibitor | Assess for ketonemia or ketonuria if symptoms suggest acidosis; stop the agent if ketoacidosis is suspected and treat promptly. ccjmccjm6. Glycemic Goals and Hypoglycemia: Standards of Care in ... | Euglycemic or mildly hyperglycemic DKA can delay recognition. ccjmccjm6. Glycemic Goals and Hypoglycemia: Standards of Care in ... |
| Impaired hypoglycemia awareness | Temporarily relax glycemic goals, provide structured education, and use CGM when appropriate. ccjmccjm6. Glycemic Goals and Hypoglycemia: Standards of Care in ... | Avoidance of recurrent hypoglycemia can improve awareness. ccjmccjm6. Glycemic Goals and Hypoglycemia: Standards of Care in ... |
| Hospitalization for noncritical illness with persistent glucose ≥180 mg/dL | Initiate or intensify insulin and/or other therapy after confirmation on two occasions within 24 hours. ccjmccjm16. Diabetes Care in the Hospital: Standards of Care in Diabetes—2024 | Hospital hyperglycemia is associated with adverse outcomes. ccjmccjm16. Diabetes Care in the Hospital: Standards of Care in Diabetes—2024 |
Acute care
Manage hospitalized hyperglycemia with scheduled therapy
Inpatient regimens should match nutritional intake and diabetes type.
For noncritically ill hospitalized adults, initiate or intensify therapy for persistent glucose ≥180 mg/dL confirmed twice within 24 hours. A glucose goal of 100–180 mg/dL is recommended in noncritical care, while 140–180 mg/dL is recommended for most critically ill adults after treatment begins. ccjmccjm16. Diabetes Care in the Hospital: Standards of Care in Diabetes—2024
Use basal insulin or basal-plus correction insulin for patients with poor intake or NPO status; use basal, prandial, and correction insulin for those eating reliably. Correction-only insulin without basal insulin is discouraged, particularly in type 1 diabetes, in whom basal insulin must continue even while NPO. ccjmccjm16. Diabetes Care in the Hospital: Standards of Care in Diabetes—2024
For type 2 diabetes hospitalized with heart failure, initiate or continue an SGLT2 inhibitor during hospitalization and at discharge after recovery from acute illness when no contraindication exists. Avoid SGLT2 inhibitors during severe illness, ketonemia or ketonuria, prolonged fasting, and surgical procedures. ccjmccjm16. Diabetes Care in the Hospital: Standards of Care in Diabetes—2024
Measure A1C on admission in people with diabetes or glucose >140 mg/dL if no result is available from the previous 3 months. ccjmccjm16. Diabetes Care in the Hospital: Standards of Care in Diabetes—2024
If using a personal CGM or automated insulin delivery system in hospital, continue only when clinically appropriate, institutional protocols and trained staff are available, and confirmatory point-of-care glucose is used for insulin dosing and hypoglycemia assessment. ccjmccjm16. Diabetes Care in the Hospital: Standards of Care in Diabetes—2024
Begin discharge planning at admission; arrange follow-up within 1 month, or in 1–2 weeks when medications changed or glycemia remains unstable. ccjmccjm16. Diabetes Care in the Hospital: Standards of Care in Diabetes—2024
Common questions
When should insulin be initiated in type 2 diabetes?
Consider insulin for symptomatic hyperglycemia, catabolic features, A1C >10%, or glucose ≥300 mg/dL. In the absence of insulin deficiency, GLP-1 receptor agonist or dual GIP/GLP-1 receptor agonist therapy is generally preferred before insulin. ccjmccjm9. Pharmacologic Approaches to Glycemic Treatment
Should SGLT2 inhibitors or GLP-1 receptor agonists be used when A1C is already at target?
Yes, when type 2 diabetes coexists with ASCVD, heart failure, or CKD and the selected agent has demonstrated relevant benefit. These therapies are recommended independent of A1C and metformin use for cardiorenal risk reduction. ccjmccjm9. Pharmacologic Approaches to Glycemic Treatment
How often should A1C be checked in stable type 2 diabetes?
Assess at least twice yearly when glycemia is stable and at goal. Check approximately every 3 months when goals are unmet, therapy changes, severe dysglycemia occurs, or health status changes. ccjmccjm6. Glycemic Goals and Hypoglycemia: Standards of Care in ...
What should prompt deintensification of diabetes therapy?
Level 2 or 3 hypoglycemia, high hypoglycemia risk, excessive treatment burden, intolerance, new contraindications, or a change in goals or life expectancy should prompt reassessment and possible deintensification. ccjm+1ccjm6. Glycemic Goals and Hypoglycemia: Standards of Care in ...ccjm9. Pharmacologic Approaches to Glycemic Treatment
What is the key concern with SGLT2 inhibitors during illness or surgery?
Euglycemic DKA. Hold SGLT2 inhibitors during severe illness, prolonged fasting, or surgery; discontinue 3–4 days before planned procedures. Evaluate ketones if acidosis symptoms occur despite nonsevere hyperglycemia. ccjm+1ccjm16. Diabetes Care in the Hospital: Standards of Care in Diabetes—2024ccjm6. Glycemic Goals and Hypoglycemia: Standards of Care in ...
References
- FDA Approves First Generic of Once-Daily GLP-1 Injection to Lower Blood Sugar in Patients with Type 2 Diabetes | FDA — www.fda.gov · www.fda.gov
- GLUCOPHAGE (metformin hydrochloride) Tablets — www.accessdata.fda.gov · www.accessdata.fda.gov
- FDA Approves First Generic Dapagliflozin Tablets — www.fda.gov · www.fda.gov
- TRESIBA® (insulin degludec) injection, for subcutaneous use — www.accessdata.fda.gov · www.accessdata.fda.gov
- 3855986 This label may not be the latest approved by FDA ... — www.accessdata.fda.gov · www.accessdata.fda.gov
- XIGDUO XR (dapagliflozin and metformin HCl extended ... — www.accessdata.fda.gov · www.accessdata.fda.gov
- Frequently Asked Questions about Labeling for Prescription Medicines | FDA — www.fda.gov · www.fda.gov
- https://nctr-crs.fda.gov/fdalabel/services/spl/ ... — nctr-crs.fda.gov · nctr-crs.fda.gov
- Diabetes Medicines — www.fda.gov · www.fda.gov
- Navigating the Complexities of Diabetes Management - Annals of Internal Medicine: Fresh Look Blog — freshlook.annals.org · freshlook.annals.org
- Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus — www.acpjournals.org · www.acpjournals.org
- Newer Pharmacologic Treatments in Adults With Type 2 ... — www.acpjournals.org · www.acpjournals.org
- Diagnosis and Management of Diabetes: Synopsis of the ... — www.acpjournals.org · www.acpjournals.org
- Pharmacologic Approaches to Glycemic Treatment of Type ... — www.acpjournals.org · www.acpjournals.org
- Systematic review of clinical practice guidelines to identify ... — www.sciencedirect.com · www.sciencedirect.com
- Drug Dosing Recommendations for All Patients: A Roadmap ... — ascpt.onlinelibrary.wiley.com · ascpt.onlinelibrary.wiley.com
- 2024 CPDD Abstract Booklet - 2024 - Wiley Online Library — accp1.onlinelibrary.wiley.com · accp1.onlinelibrary.wiley.com
- Type 2 diabetes in adults: management | Guidance — www.nice.org.uk · www.nice.org.uk
- 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 — www.ccjm.org · www.ccjm.org
- 9. Pharmacologic Approaches to Glycemic Treatment — www.ccjm.org · www.ccjm.org
- 16. Diabetes Care in the Hospital: Standards of Care in Diabetes—2024 — www.ccjm.org · www.ccjm.org
- Initial medicines | Type 2 diabetes in adults: management | Guidance | NICE — www.nice.org.uk · www.nice.org.uk
- 6. Glycemic Goals and Hypoglycemia: Standards of Care in ... — www.ccjm.org · www.ccjm.org
- Tests for Screening and Diagnosis of Type 2 Diabetes — diabetesjournals.org · diabetesjournals.org